human interferon alpha 2b / Generic mfg. - LARVOL DELTA

Clinical and virological course of patients with coronavirus disease 2019 in Jiangsu province, China: a retrospective, multi-center cohort study. (PubMed, Virol J) - "Twenty (6.1%) patients were admitted to the ICU, while no patient was deceased. Our study found that age > 60 years was associated with the delayed SARS-CoV-2 clearance, while treated with atomized inhalation of interferon α-2b could promote the clearance of SARS-CoV-2."

Journal • Retrospective data • Acute Respiratory Distress Syndrome • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Risk factors of liver injury in patients with coronavirus disease 2019 in Jiangsu, China: a retrospective, multi-center study. (PubMed, J Med Virol) - "Age over 50 years (odds ratio [OR] 2.086, 95% confidence interval [CI] 1.030-4.225, P=0.041), male sex (OR 2.737, 95%CI 1.418-5.284, P=0.003), and lopinavir-ritonavir (OR 2.504, 95%CI 1.187-5.283, P=0.016) were associated with higher risk of liver function abnormality, while the atomized inhalation of interferon α-2b (OR 0.256, 95%CI 0.126-0.520, P<0.001) was associated with reduced risk of liver function abnormality during hospitalization...Mild to moderate liver injury was common in COVID-19 patients in Jiangsu, China. Age over 50 years, male sex, and lopinavir-ritonavir were the independent risk factors of liver impairment in COVID-19 patients during hospitalization."

Journal • Hepatology • Infectious Disease • Liver Failure • Novel Coronavirus Disease • Respiratory Diseases

Study: Interferons treatment speeds Covid-19 virus removal by 7 days (Laboratory Equipment) - "In a limited, non-randomized study...the research team showed interferons significantly accelerated viral clearance and also reduced levels of inflammatory proteins in moderately ill COVID-19 patients....The current study evaluated 77 patients with moderate COVID-19 symptoms admitted to hospitals in Wuhan, China between January 16 and February 20, 2020. The results suggest interferon (IFN)- α2b accelerates viral clearance by 7.6 days compared with other drugs....The next step is a controlled clinical trial with a larger group of infected patients, taking into account age, sex and comorbidities, who are randomized to receive treatment or placebo."

Clinical data • Cytokine storm • New trial • Infectious Disease • Novel Coronavirus Disease

BetterLife Pharma announces interferon alpha-2b Covid-19 news regarding its emergence as a potential treatment for Covid-19 (PRNewswire) - "BetterLife Pharma Inc....today announced that a third party study is scheduled to be released this Friday in the journal Frontiers of Immunology. The study investigated the use of interferon alpha-2b on 77 patients with moderate cases of COVID-19 and found that the interferon alpha-2b drug significantly accelerated clearance of the virus from the airways of patients. This study was subject to an article titled 'Interferon emerges as potential treatment for COVID-19' in the May 13th edition of the Globe and Mail..."

Clinical • Infectious Disease • Novel Coronavirus Disease

Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19) (clinicaltrials.gov) - P=N/A; N=18; Active, not recruiting; Sponsor: Second Affiliated Hospital of Wenzhou Medical University; Enrolling by invitation ➔ Active, not recruiting; N=60 ➔ 18

Clinical • Enrollment change • Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases